Microneedling Alone vs Microneedling With PRP in the Treatment of Macular Amyloidosis; a Split Face Comparative Study

N/ANot Yet RecruitingNCT07360860

Cairo University30 enrolled

Overview

This study is going to asses and compare the efficacy of treatment of macular amyloidosis using microneedling vs PRP with microneedling. Pruritus and pigmentation will be assessed.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Macular Amyloidosis

Interventions

microneedlingDEVICE

microneedling will be done for the one arm of macular amyloidosis

microneedling with PRPDEVICE

microneedling with PRP will be done on macular amyloidosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: • Both genders were included. * Patients above 18 years old. * Patients diagnosed by macular amyloidosis, proved by dermoscopy and histopathology. Exclusion Criteria: • Prior use of topical therapies in the previous 4 weeks. * Prior use of any procedures such as chemical peel or laser treatment in the previous 1 month. * Prior use of any systemic treatment for macular amyloidosis in the past 12 weeks. * Patients with other skin conditions (e.g., psoriasis, eczema). * Immunocompromised patients (HIV, chemotherapy). * Patients with history of any type of autoimmune disorders, coagulopathies, and keloid tendency. * Known or suspected allergy to ingredients

Outcomes

Primary Outcomes

Improvement of macular amyloidosis using microneedling or PRP with microneedling

1. The clinical assessment will be performed based on the photographs taken at baseline, after 1month, and 3 months of the last session. 2. Results will be measured by the Quartile grading scale: 1\< 25% improvement 2=25-\<50% improvement 3=50-\<75% improvement 4\> 75% improvement 3. Degree of improvement in dermoscopic features will be measured by scoring system as follows : 0-25% = 0 (no improvement) 26-50% = 1(mild improvement) 51-75% = 2 (moderate improvement) 76- 100% = 3 (marked improvement) 4. Patients' satisfaction: Visual Analog Score for pain 5.measuring the Treatment Satisfaction Questionnaire for Medication (TSQM) for effectiveness. 6\. TPhysician global satisfaction will be assessed. 0-3 (unsatisfied) 4-6 (satisfied) 7-10 (highly satisfied)

Time frame: 3 months

Central Contacts

Amira Elbendary, MD

CONTACT

+201552208664 aelbendary@kasralainy.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.